title: Tyrosine kinase inhibitor usage, treatment outcome, and prognostic scores in CML: report from the population-based Swedish CML registry.
abstract: Clinical management guidelines on malignant disorders are generally based on data from clinical trials with selected patient cohorts. In Sweden, more than 95% of all patients diagnosed with chronic myeloid leukemia (CML) are reported to the national CML registry, providing unique possibilities to compile population-based information. This report is based on registry data from 2002 to 2010, when a total of 779 patients (425 men, 354 women; median age, 60 years) were diagnosed with CML (93% chronic, 5% accelerated, and 2% blastic phase) corresponding to an annual incidence of 0.9/100,000. In 2002, approximately half of the patients received a tyrosine kinase inhibitor as initial therapy, a proportion that increased to 94% for younger (<70 years) and 79% for older (>80 years) patients during 2007-2009. With a median follow-up of 61 months, the relative survival at 5 years was close to 1.0 for patients younger than 60 years and 0.9 for those aged 60 to 80 years, but only 0.6 for those older than 80 years. At 12 months, 3% had progressed to accelerated or blastic phase. Sokal, but not European Treatment and Outcome Study, high-risk scores were significantly linked to inferior overall and relative survival. Patients living in university vs nonuniversity catchment areas more often received tyrosine kinase inhibitors up front but showed comparable survival.
authors.affiliation: Department of Medical Science and Division of Hematology, University Hospital, Uppsala, Sweden. martin.hoglund@medsci.uu.se
authors.forename: Martin
authors.initials: M
authors.lastname: Höglund
authors.forename: Fredrik
authors.initials: F
authors.lastname: Sandin
authors.forename: Karin
authors.initials: K
authors.lastname: Hellström
authors.forename: Mats
authors.initials: M
authors.lastname: Björeman
authors.forename: Magnus
authors.initials: M
authors.lastname: Björkholm
authors.forename: Mats
authors.initials: M
authors.lastname: Brune
authors.forename: Arta
authors.initials: A
authors.lastname: Dreimane
authors.forename: Marja
authors.initials: M
authors.lastname: Ekblom
authors.forename: Sören
authors.initials: S
authors.lastname: Lehmann
authors.forename: Per
authors.initials: P
authors.lastname: Ljungman
authors.forename: Claes
authors.initials: C
authors.lastname: Malm
authors.forename: Berit
authors.initials: B
authors.lastname: Markevärn
authors.forename: Kristina
authors.initials: K
authors.lastname: Myhr-Eriksson
authors.forename: Lotta
authors.initials: L
authors.lastname: Ohm
authors.forename: Ulla
authors.initials: U
authors.lastname: Olsson-Strömberg
authors.forename: Anders
authors.initials: A
authors.lastname: Själander
authors.forename: Hans
authors.initials: H
authors.lastname: Wadenvik
authors.forename: Bengt
authors.initials: B
authors.lastname: Simonsson
authors.forename: Leif
authors.initials: L
authors.lastname: Stenke
authors.forename: Johan
authors.initials: J
authors.lastname: Richter
mesh_terms: D000293:Adolescent; D000328:Adult; D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy / Q000453:epidemiology / Q000401:mortality*; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors*; D012042:Registries / Q000706:statistics & numerical data*; D012737:Sex Factors; D015996:Survival Rate; D013548:Sweden / Q000453:epidemiology; D055815:Young Adult
chemical_list: D047428:Protein Kinase Inhibitors; D011505:Protein-Tyrosine Kinases